METHODS: The authors performed a MEDLINE search inclusive of articles from January 1987 (advent of DBS literature) to June 2023 including human and modeling studies written in English. For longevity of therapy data, only studies with a mean follow-up of ≥three years were included. Using the Rayyan platform, two reviewers (JP and RM) performed a title screen. Of the 734 articles, 205 were selected by title screen and 109 from abstract review. Ultimately, a total of 122 articles were reviewed. The research questions we explored were 1) how long can the different components of the DBS system maintain functionality? and 2) how long can DBS remain efficacious in treating Parkinson\'s disease (PD), essential tremor (ET), dystonia, and other disorders?
RESULTS: We showed that patients with PD, ET, and dystonia maintain a considerable long-term benefit in motor scores seven to ten years after implant, although the percentage improvement decreases over time. Stimulation off scores in PD and ET show worsening, consistent with disease progression. Battery life varies by the disease treated and the programming settings used. There remains a paucity of literature after ten years, and the impact of new device technology has not been classified to date.
CONCLUSIONS: We reviewed existing data on DBS longevity. Overall, outcomes data after ten years of therapy are substantially limited in the current literature. We recommend that physicians who have data for patients with DBS exceeding this duration publish their results.
方法:作者进行了MEDLINE搜索,其中包括从1987年1月(DBS文献出现)到2023年6月的文章,其中包括用英语编写的人体和建模研究。对于治疗数据的寿命,仅纳入平均随访≥3年的研究.使用Rayyan平台,两名审阅者(JP和RM)执行了标题屏幕。在734篇文章中,通过标题屏幕选择了205个,从摘要评论中选择了109个。最终,共审查了122篇文章。我们探索的研究问题是:1)DBS系统的不同组件可以维持功能多长时间?2)DBS在治疗帕金森氏病(PD)方面可以保持有效的时间。特发性震颤(ET),肌张力障碍,和其他疾病?
结果:我们显示患有PD的患者,ET,和肌张力障碍在植入后7到10年的运动评分中保持了相当大的长期益处,虽然百分比改善随着时间的推移而下降。PD和ET的刺激评分显示恶化,与疾病进展一致。电池寿命因治疗的疾病和使用的编程设置而异。十年后仍然缺乏文学,迄今为止,尚未对新设备技术的影响进行分类。
结论:我们回顾了有关DBS寿命的现有数据。总的来说,治疗10年后的结局数据在目前的文献中基本上是有限的.我们建议拥有超过此持续时间的DBS患者数据的医生发布其结果。